Stay updated on QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial
Sign up to get notified when there's something new on the QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial page.

Latest updates to the QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page now presents the study record for Novartis’s completed Phase 2 QBW251 dose-range trial in people with COPD, including study methods, outcome measures, participant eligibility, locations, and documents.SummaryDifference100%

- Check15 days agoChange DetectedThe ClinicalTrials.gov footer revision identifier changed from v3.7.2 to v3.8.0. The study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check29 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check36 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check57 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, replacing the usual trial details with an error screen. This indicates restricted access to the trial information rather than a metadata change.SummaryDifference18%

- Check78 days agoChange DetectedRevision: v3.6.6 updates the page version from v3.6.5 to v3.6.6. This change signals a newer build of the page and does not appear to alter study content or user-facing details.SummaryDifference0.0%

Stay in the know with updates to QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the QBW251 Dose-range Efficacy & Safety in COPD Clinical Trial page.